Literature DB >> 16601876

Manifestations of Fabry disease in placental tissue.

A C Vedder1, A Strijland, M A vd Bergh Weerman, S Florquin, J M F G Aerts, C E M Hollak.   

Abstract

Fabry disease is an X-linked lysosomal storage disorder caused by deficiency of the lysosomal enzyme alpha-galactosidase A. Manifestations of the disease in placental tissue have been reported only twice. We report for the first time on the biochemical, histological and genetic features of two cases: placenta A derived from a mother heterozygous for Fabry disease who gave birth to a hemizygous son, and placenta B obtained from a healthy mother who carried a heterozygous daughter. Biopsies of placentae A, B and of four healthy controls were taken directly after birth. Assessment of alpha-galactosidase A (alpha-Gal) activity was performed both in fetal leukocytes (derived from umbilical cord blood) and in the biopsy specimens. The tissue was further examined by electron microscopy, immunohistochemistry and biochemical analysis for the presence of storage material (ceramide trihexoside (CTH)). In placenta A, characteristic zebra bodies reflecting accumulated storage material were seen in all biopsies evaluated. CTH values were markedly elevated as compared to the controls and alpha-Gal activity in both fetal leukocytes and placental tissue was very low. Placenta B showed no storage material at all. CTH values were within the control range. alpha-Gal activity ranged from intermediate to near normal; enzyme activity in fetal leukocytes was significantly decreased. As placental tissue is mainly derived from fetal cells, we may conclude that, in a boy suffering from Fabry disease, extensive storage of CTH is already present at birth. As complications develop only around the age of 10 years, it may be not the CTH itself but secondary processes that cause cellular and organ damage.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16601876     DOI: 10.1007/s10545-006-0196-0

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  15 in total

1.  Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.

Authors:  C M Eng; N Guffon; W R Wilcox; D P Germain; P Lee; S Waldek; L Caplan; G E Linthorst; R J Desnick
Journal:  N Engl J Med       Date:  2001-07-05       Impact factor: 91.245

2.  Uneven X inactivation in a female monozygotic twin pair with Fabry disease and discordant expression of a novel mutation in the alpha-galactosidase A gene.

Authors:  I Redonnet-Vernhet; J K Ploos van Amstel; R P Jansen; R A Wevers; R Salvayre; T Levade
Journal:  J Med Genet       Date:  1996-08       Impact factor: 6.318

3.  [Fetal pathology in Fabry's disease and mucopolysaccharidosis type I].

Authors:  M Elleder; H Poupĕtová; V Kozich
Journal:  Cesk Patol       Date:  1998-01

4.  Corneal findings in a foetus with Fabry's disease.

Authors:  A Tsutsumi; Y Uchida; T Kanai; O Tsutsumi; K Satoh; S Sakamoto
Journal:  Acta Ophthalmol (Copenh)       Date:  1984-12

5.  Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency.

Authors:  R O Brady; A E Gal; R M Bradley; E Martensson; A L Warshaw; L Laster
Journal:  N Engl J Med       Date:  1967-05-25       Impact factor: 91.245

6.  Demonstration of Fabry's disease deposits in placenta.

Authors:  S Popli; D J Leehey; Z V Molnar; Z M Nawab; T S Ing
Journal:  Am J Obstet Gynecol       Date:  1990-02       Impact factor: 8.661

7.  Enzyme replacement therapy in Fabry disease: a randomized controlled trial.

Authors:  R Schiffmann; J B Kopp; H A Austin; S Sabnis; D F Moore; T Weibel; J E Balow; R O Brady
Journal:  JAMA       Date:  2001-06-06       Impact factor: 56.272

8.  The frequency of lysosomal storage diseases in The Netherlands.

Authors:  B J Poorthuis; R A Wevers; W J Kleijer; J E Groener; J G de Jong; S van Weely; K E Niezen-Koning; O P van Diggelen
Journal:  Hum Genet       Date:  1999 Jul-Aug       Impact factor: 4.132

9.  Measurement of protein using bicinchoninic acid.

Authors:  P K Smith; R I Krohn; G T Hermanson; A K Mallia; F H Gartner; M D Provenzano; E K Fujimoto; N M Goeke; B J Olson; D C Klenk
Journal:  Anal Biochem       Date:  1985-10       Impact factor: 3.365

10.  Fabry's disease: alpha-galactosidase deficiency.

Authors:  J A Kint
Journal:  Science       Date:  1970-02-27       Impact factor: 47.728

View more
  30 in total

1.  The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels.

Authors:  A C Vedder; G E Linthorst; M J van Breemen; J E M Groener; F J Bemelman; A Strijland; M M A M Mannens; J M F G Aerts; C E M Hollak
Journal:  J Inherit Metab Dis       Date:  2007-01-05       Impact factor: 4.982

Review 2.  Lysosomal storage disorders in the newborn.

Authors:  Orna Staretz-Chacham; Tess C Lang; Mary E LaMarca; Donna Krasnewich; Ellen Sidransky
Journal:  Pediatrics       Date:  2009-04       Impact factor: 7.124

3.  Toward a consensus in the laboratory diagnostics of Fabry disease - recommendations of a European expert group.

Authors:  Andreas Gal; Derralynn A Hughes; Bryan Winchester
Journal:  J Inherit Metab Dis       Date:  2011-01-13       Impact factor: 4.982

4.  A Retrospective Survey Studying the Impact of Fabry Disease on Pregnancy.

Authors:  Alexandrea Holmes; Dawn Laney
Journal:  JIMD Rep       Date:  2015-02-22

5.  Elevated globotriaosylsphingosine is a hallmark of Fabry disease.

Authors:  Johannes M Aerts; Johanna E Groener; Sijmen Kuiper; Wilma E Donker-Koopman; Anneke Strijland; Roelof Ottenhoff; Cindy van Roomen; Mina Mirzaian; Frits A Wijburg; Gabor E Linthorst; Anouk C Vedder; Saskia M Rombach; Josanne Cox-Brinkman; Pentti Somerharju; Rolf G Boot; Carla E Hollak; Roscoe O Brady; Ben J Poorthuis
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

Review 6.  Enzyme replacement therapy for Fabry disease: a systematic review of available evidence.

Authors:  Roland M Schaefer; Anna Tylki-Szymańska; Max J Hilz
Journal:  Drugs       Date:  2009-11-12       Impact factor: 9.546

Review 7.  Fabry's disease: an example of cardiorenal syndrome type 5.

Authors:  Aashish Sharma; Marco Sartori; Jose J Zaragoza; Gianluca Villa; Renhua Lu; Elena Faggiana; Alessandra Brocca; Luca Di Lullo; Sandro Feriozzi; Claudio Ronco
Journal:  Heart Fail Rev       Date:  2015-11       Impact factor: 4.214

8.  Enzyme replacement therapy in a patient of heterozygous Fabry disease: clinical and pathological evaluations by repeat kidney biopsy and a successful pregnancy.

Authors:  Yoichi Iwafuchi; Hiroki Maruyama; Tetsuo Morioka; Seiko Noda; Hiroshi Nagata; Yuko Oyama; Ichiei Narita
Journal:  CEN Case Rep       Date:  2017-10-10

Review 9.  Paediatric Fabry disease.

Authors:  Carolyn Ellaway
Journal:  Transl Pediatr       Date:  2016-01

10.  Fabry disease in children and the effects of enzyme replacement treatment.

Authors:  Guillem Pintos-Morell; Michael Beck
Journal:  Eur J Pediatr       Date:  2009-02-26       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.